Clark, J. M. The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol. 40(Suppl 1), S5–S10 (2006).
Targher, G. & Arcaro, G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 191, 235–240 (2007).
Noureddin, M., Mato, J. M. & Lu, S. C. Nonalcoholic fatty liver disease: Update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp. Biol. Med. (Maywood) 240, 809–820 (2015).
Mato, J. M. & Lu, S. C. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology 45, 1306–1312 (2007).
Bottiglieri, T. S-Adenosyl-L-methionine (SAMe): From the bench to the bedside—Molecular basis of a pleiotrophic molecule. Am. J. Clin. Nutr. 76, 1151s–1157s (2002).
Halsted, C. H. et al. Folate deficiency disturbs hepatic methionine metabolism and promotes liver injury in the ethanol-fed micropig. Proc. Natl. Acad. Sci. U.S.A. 99, 10072–10077 (2002).
Hirsch, S. et al. Serum folate and homocysteine levels in obese females with non-alcoholic fatty liver. Nutrition 21, 137–141 (2005).
Koplay, M., Gulcan, E. & Ozkan, F. Association between serum vitamin B12 levels and the degree of steatosis in patients with nonalcoholic fatty liver disease. J. Investig. Med. 59, 1137–1140 (2011).
Polyzos, S. A. et al. Serum vitamin B12 and folate levels in patients with non-alcoholic fatty liver disease. Int. J. Food Sci. Nutr. 63, 659–666 (2012).
Prati, D. et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med. 137, 1–10 (2002).
Kwok, T. et al. A randomized placebo controlled trial of vitamin B12 supplementation to prevent cognitive decline in older diabetic people with borderline low serum vitamin B12. Clin. Nutr. 36, 1509–1515 (2017).
Romero-Gómez, M., Zelber-Sagi, S. & Trenell, M. Treatment of NAFLD with diet, physical activity and exercise. J. Hepatol. 67, 829–846 (2017).
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016).
Craig, C. L. et al. International physical activity questionnaire: 12-country reliability and validity. Med. Sci. Sports Exerc. 35, 1381–1395 (2003).
Chimoriya, R., Piya, M. K., Simmons, D., Ahlenstiel, G. & Ho, V. The use of two-dimensional shear wave elastography in people with obesity for the assessment of liver fibrosis in non-alcoholic fatty liver disease. J. Clin. Med. 10, 95 (2020).
Lee, D. H. et al. Accuracy of two-dimensional shear wave elastography and attenuation imaging for evaluation of patients with nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 19, 797–805 (2021).
Zaleska-Dorobisz, U. et al. The evaluation of liver fibrosis in the real-time shear wave elastography technique in chronic hepatitis B and C patients: How many measurements are necessary to assign patients to METAVIR score properly? Hepat. Mon. 18, e61189 (2018).
Botsoglou, N. A. et al. Rapid, sensitive, and specific thiobarbituric acid method for measuring lipid peroxidation in animal tissue, food, and feedstuff samples. J. Agric. Food Chem. 42, 1931–1937 (1994).
Xu, Y., Guan, Y., Yang, X., Xia, Z. & Wu, J. Association of serum homocysteine levels with histological severity of NAFLD. J. Gastrointest. Liver Dis. 29, 51–58 (2020).
de Carvalho, S. C. et al. Plasmatic higher levels of homocysteine in non-alcoholic fatty liver disease (NAFLD). Nutr. J. 12, 37 (2013).
Gulsen, M. et al. Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 20, 1448–1455 (2005).
Ai, Y. et al. Homocysteine induces hepatic steatosis involving ER stress response in high methionine diet-fed mice. Nutrients 9, 346 (2017).
Polyzos, S. A. et al. Serum homocysteine levels in patients with nonalcoholic fatty liver disease. Ann. Hepatol. 11, 68–76 (2012).
Dai, Y., Zhu, J., Meng, D., Yu, C. & Li, Y. Association of homocysteine level with biopsy-proven non-alcoholic fatty liver disease: a meta-analysis. J. Clin. Biochem. Nutr. 58, 76–83 (2016).
Werstuck, G. H. et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J. Clin. Investig. 107, 1263–1273 (2001).
Werge, M. P. et al. The role of the transsulfuration pathway in non-alcoholic fatty liver disease. J. Clin. Med. 10, 1081 (2021).
Cordero, P., Gomez-Uriz, A. M., Campion, J., Milagro, F. I. & Martinez, J. A. Dietary supplementation with methyl donors reduces fatty liver and modifies the fatty acid synthase DNA methylation profile in rats fed an obesogenic diet. Genes Nutr. 8, 105–113 (2013).
Pooya, S. et al. Methyl donor deficiency impairs fatty acid oxidation through PGC-1alpha hypomethylation and decreased ER-alpha, ERR-alpha, and HNF-4alpha in the rat liver. J. Hepatol. 57, 344–351 (2012).
Jacobs, R. L., Lingrell, S., Zhao, Y., Francis, G. A. & Vance, D. E. Hepatic CTP: Phosphocholine cytidylyltransferase-alpha is a critical predictor of plasma high density lipoprotein and very low density lipoprotein. J. Biol. Chem. 283, 2147–2155 (2008).
Zhao, Y. et al. Lack of phosphatidylethanolamine N-methyltransferase alters plasma VLDL phospholipids and attenuates atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 29, 1349–1355 (2009).
Abdulkhaleq, F. M. et al. Antioxidative stress effects of vitamins C, E, and B(12), and their combination can protect the liver against acetaminophen-induced hepatotoxicity in rats. Drug Des. Dev. Ther. 12, 3525–3533 (2018).
Monserrat-Mesquida, M. et al. Oxidative stress and pro-inflammatory status in patients with non-alcoholic fatty liver disease. Antioxidants (Basel) 9, 759 (2020).
Zelber-Sagi, S. et al. Serum malondialdehyde is associated with non-alcoholic fatty liver and related liver damage differentially in men and women. Antioxidants (Basel) 9, 759 (2020).
Bayés, B., Pastor, M. C., Bonal, J., Juncà, J. & Romero, R. Homocysteine and lipid peroxidation in haemodialysis: Role of folinic acid and vitamin E. Nephrol. Dial. Transplant. 16, 2172–2175 (2001).
Racek, J., Rusnáková, H., Trefil, L. & Siala, K. K. The influence of folate and antioxidants on homocysteine levels and oxidative stress in patients with hyperlipidemia and hyperhomocysteinemia. Physiol. Res. 54, 87–95 (2005).
Aghamohammadi, V., Gargari, B. P. & Aliasgharzadeh, A. Effect of folic acid supplementation on homocysteine, serum total antioxidant capacity, and malondialdehyde in patients with type 2 diabetes mellitus. J. Am. Coll. Nutr. 30, 210–215 (2011).
Armandi, A., Rosso, C., Caviglia, G. P. & Bugianesi, E. Insulin resistance across the spectrum of nonalcoholic fatty liver disease. Metabolites 11, 155 (2021).
Li, Z. et al. Folate and vitamin B12 status is associated with insulin resistance and metabolic syndrome in morbid obesity. Clin. Nutr. 37, 1700–1706 (2018).
Iglesia, I. et al. Associations between insulin resistance and three B-vitamins in European adolescents: The HELENA study. Nutr. Hosp. 34, 568–577 (2017).
Al-Daghri, N. M. et al. Association of vitamin B12 with pro-inflammatory cytokines and biochemical markers related to cardiometabolic risk in Saudi subjects. Nutrients 8, 460 (2016).
Kurt, R. et al. Folic Acid and vitamin B12 supplementation improves coronary flow reserve in elderly subjects with vitamin B12 deficiency. Arch. Med. Res. 41, 369–372 (2010).
Setola, E. et al. Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: Relationship between homocysteine levels and hyperinsulinemia. Eur. J. Endocrinol. 151, 483–489 (2004).
Satapathy, S., Bandyopadhyay, D., Patro, B. K., Khan, S. & Naik, S. Folic acid and vitamin B12 supplementation in subjects with type 2 diabetes mellitus: A multi-arm randomized controlled clinical trial. Complement Ther. Med. 53, 102526 (2020).
Najib, S. & Sánchez-Margalet, V. Homocysteine thiolactone inhibits insulin signaling, and glutathione has a protective effect. J. Mol. Endocrinol. 27, 85–91 (2001).